|
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia Clinical research trials and Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia. Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia clinical trial. Participants oftentimes recieve the most expert healthcare available for their Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia  Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia
For Condition: Acute Myeloid Leukemia
Status: Recruiting
Sponsor(s): University of Alabama , ILEX Products
Synopsis: The purpose of this study is to determine the recommended phase II dose of clofarabine when administered in combination with standard dose Ara-C to older (>=60 years of age) patients with newly diagnosed acute myeloid leukemia (AML).
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 60 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Have newly diagnosed AML (FAB classification types M0-M2 or M4-M7 or WHO classification) excluding acute promyelocytic leukemia (APL) or AML with any of the following chromosomal translocations: t(15;17)(q22;q21); t(11;17)(q23;q21); t(11;17)(q13;q21); t(5;17)(q32;q12).. - Have greater than or equal to 20% blasts in the bone marrow. - Have greater than or equal to 20% cellularity in the bone marrow. - Provide written informed consent. - Must be 60 years of age at diagnosis. - Have an Karnofsky performance status of 60. - Women of childbearing potential (<1 year post-menopausal unless surgically sterilized) and sexually active males must have a negative urine pregnancy test, and agree to use an effective barrier method of birth control (i.e. latex condom, diaphragm, cervical cap, etc) to avoid pregnancy. - Able to comply with study procedures and follow-up examinations. - Have adequate organ function as indicated by the following laboratory values, obtained within 7 days prior to registration: Parameter Required Value (IS units) Renal Serum creatinine <2.0 mg/dL Hepatic Serum bilirubin <2 x ULN AST and ALT 5 x ULN ULN = Institutional Upper Limit of Normal. Inclusion Laboratory Values Exclusion Criteria: - Patients with pre-existing myelodysplastic syndrome, or with antecedent hematologic disorder of >3 months duration, will be excluded. Those with concomitant myelodysplasia/trilineage dysplasia noted at the time of diagnosis of AML will be eligible 74 - Have secondary AML (AML following chemotherapy or radiation therapy). - Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment. - Have a psychiatric disorder(s) that would interfere with consent, study participation or follow-up. - Are receiving other chemotherapy or corticosteroids (unless the latter is administered at a low dose for pre-medication purposes or for the treatment of chronic conditions – e.g., rheumatoid arthritis). - Have received prior treatment for leukemia. Patients who have received growth factors, cytokine support, leukapheresis, hydroxyurea, or cranial irradiation will be allowed but must discontinue treatment at least 24 hours prior to beginning treatment with clofarabine. If used, hydroxyurea must be discontinued 48 hours prior to the initiation of chemotherapy. - Have any other severe concurrent disease (severe coronary artery disease (NYHA class >II), significant neurological disorder, uncontrolled diabetes, etc.), which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. - Have active central nervous system involvement with leukemia. - Other malignancy within the past year, with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin
Total Enrollment: 46
Location and Contact Information:
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35233
United States
Recruiting Lynda Leo 205-975-9481
Additional Information:
Study ID Numbers: UAB 0341;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00081822
Other Acute Myeloid Leukemia Studies:
1. Phase 2 Study of ZARNESTRAâ„¢ as Postconsolidation Therapy for Acute Myeloid Leukemia in Subjects 60 Years & Older
2. Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
3. Fluconazole Compared With Voriconazole in Preventing Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Transplantation
4. Study of CEP-701 in Patients with Acute Myeloid Leukemia (AML)
5. An open-label, phase II trial of PKC412 monotherapy in patients with acute myeloid leukemia and patients with myelodysplastic syndrome
Related Studies:
Other Acute Myeloid Leukemia Clinical Trials
Other Alabama Clinical Trials
Other Birmingham Clinical Trials
Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults with Acute Myeloid Leukemia
|
|
|
|
|
|
|
|
